Hillevax Inc (HLVX) Return on Investment ROI from the second quarter of 2025 to second quarter of 2024 and for the year 2025, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
Hillevax Inc's ROI from its second quarter of 2025 to the second quarter of 2024 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Hillevax Inc's ROI in the second quarter of 2025?
Hillevax Inc recorded a cumulative net loss of $-71 million during 12 months ending in the second quarter of 2025, resulting in a negative return on investment (ROI) of -39.28%.
Within the Healthcare sector 464 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2025 quarter, so far to 3753, from total ROI ranking in the first quarter of 2025 at 3962.
HilleVax Inc Faces Tumultuous Waters: 2024 Struggles Amid Norovirus Vaccine Setbacks and Workforce Reductions In an unforgiving landscape fueled by rigorous competition and increasing economic pressures, HilleVax Inc. (NASDAQ: HLVX), a Boston-based biopharmaceutical company, is currently experiencing significant challenges in the market, trailing with a performance 12.32% below that of the broader industry this year. Having recorded a staggering cumulative net loss totaling $108 million in the twelve months ending in the third quarter of 2023, HilleVax has seen its return on investment (ROI) plummet to -35.87%. As the company grapples with these financial headwinds, a recent series of staffing reductions and operational scaling raises questions about its future trajectory.The current discontent surrounding HilleVax shares can largely be traced back to a disappointing outcome from its Phase IIb clinical trial for its lead norovirus vaccine, which catalyzed a wave of negative market sentiment. On August 1, 2024, just after the announcement of the trial failure, HilleVax revealed plans to cut approximately 40% of its workforce amounting to the layoff of 41 employees as part of its efforts to streamline operations. This decision directly points to the profound impact of clinical setbacks on personnel decisions within biotechnology sectors. Moreover, the clinical trial results not only led to immediate workforce adjustments but also prompted deeper investigations by law firms on behalf of investors regarding potential claims against the company.
BOSTON, July 31, 2024 - HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company specializing in developing and commercializing innovative vaccines, has revealed plans to downsize its workforce in a bid to reduce operational expenses. The company intends to lay off approximately 41 employees, which amounts to around 40% of its workforce, as a strategic move to preserve cash while continuing the development of its HIL-214 and HIL-216 norovirus vaccine candidates, as well as drive business development activities in support of these vaccines. This decision comes at a time when HilleVax has encountered significant financial challenges. Over the past 30 days, their stock, HLVX, has experienced a substantial decline of -87%. Moreover, data shows that Hillevax Inc recorded a cumulative net loss of $-108 million during the twelve-month period ending in the third quarter of 2023, leading to a negative return on investment (ROI) of -35.87%. This places the company among the lower performers in terms of ROI within the healthcare sector, with 470 other companies boasting higher returns on investment.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
